AHA Coding Clinic® for ICD-10-CM and ICD-10-PCS - 2021 Issue 4; Section X-New Technology
Chimeric Antigen Receptor T-Cell Immunotherapy
Chimeric Antigen Receptor (CAR) T-cell immunotherapy is a cell-based gene therapy in which immune cells are removed from a patient, armed with new proteins that allow them to recognize cancer, and then reinfused into the patient in large numbers. These cells persist in the body, becoming “living drugs.” Changes have been made to resolve the conflict for the intravenous administration of CAR T-cell therapies, which had been classified to two different tables. The two codes in Table XW0, Anatomical Regions, Introduction, were not product-specific, with Substance value C, Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy. Yescarta® (axicabtagene...
Subscribe or sign in to view the full article.
Article Overview
This article explains recent ICD-10-PCS updates for CAR T-cell immunotherapy and describes the broader classification changes affecting these therapies. It is aimed at coding professionals and others who need to understand how the evolving therapy landscape is reflected in the code tables, including product-specific and non-product-specific distinctions, new technology groupings, and newly added products. The article also provides background on the therapies themselves and summarizes the types of coding updates made for current and emerging CAR T-cell products.
Why This Topic Matters
CAR T-cell therapies continue to evolve quickly, and coding updates are needed to keep the classification system aligned with new products and therapy types. Understanding the scope of these changes helps coding staff, CDI teams, and reimbursement professionals follow current guidance and recognize when updates have been made to existing code tables.
Article Sections
-
Overview of CAR T-cell immunotherapy
Introduces CAR T-cell immunotherapy and explains the general therapy concept. Provides context for the classification discussion that follows.
-
ICD-10-PCS classification changes for CAR T-cell therapies
Summarizes updates to the ICD-10-PCS tables and describes the broader reorganization of CAR T-cell therapy reporting. Covers the transition from older table assignments to updated classifications.
-
Non-product-specific and product-specific substance values
Describes the creation and revision of substance values used to distinguish different CAR T-cell immunotherapy groupings. Notes how the article presents both non-product-specific and product-specific updates.
-
New and existing CAR T-cell products
Lists the therapies addressed in the update and places them within the article’s broader coding context. Includes discussion of established products and newer therapies.
-
Ciltacabtagene autoleucel
Provides a therapy-specific background summary for one of the newer CAR T-cell products. Focuses on the treatment’s general clinical context and development.
-
Idecabtagene vicleucel
Provides a therapy-specific background summary for another newer CAR T-cell product. Includes general information about the therapy and its administration setting.
What You Will Learn
- How CAR T-cell immunotherapy is classified in ICD-10-PCS
- What kinds of classification changes were made for these therapies
- How product-specific and non-product-specific updates are organized
- Which newer CAR T-cell products are discussed in the article
- What background information is provided for selected therapies
Who Should Read This
- Medical coders
- Coding auditors
- Clinical documentation integrity professionals
- Reimbursement specialists
- Health information management professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com